Opdivo did not improve overall survival in ONO-4538-23 study for recurrent ovarian cancer.- Ono + BMS
Related news and insights
National Institute for Health and Clinical Excellence (NICE) recommends; Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer . Technology appraisal guidance [TA784]Published: 20 April 2022.
Clovis Oncology announced positive top-line data from the monotherapy arm of the phase III ATHENA (GOG 3020/ENGOT-ov45) trial (ATHENA-MONO) demonstrating that Rubraca (rucaparib) as maintenance treatment for ovarian cancer successfully achieved the primary endpoint of significantly improved investigator-assessed progression-free survival (PFS) compared with placebo.
Novocure announced the results of a pre-specified interim analysis for the phase III pivotal INNOVATE-3 study evaluating the safety and efficacy of Tumor Treating Fields (TTFields) Optune + paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.